Company intelligence / Profile preview
Philochem AG
Otelfingen, Zurich, Switzerlandphilochem.ch ↗
- Ownership
- Public · PHIL
- Employees
- ~25
- Development stage
- Phase 3
01
Overview
Several programs are in early clinical development. Notably:
- PHC-102 for renal cell carcinoma in Phase I.
- [68Ga]Ga-OncoFAP for solid tumors in Phase I.
- Ga-OncoCAlX targeting CAIX for renal cell carcinoma at IND stage.
- Ga-OncoACP3 targeting ACP3 for prostate cancer at IND stage.
Philogen group’s lead asset Onfekafusp alfa/L19TNF (“Fibromun”) is in a pivotal Phase III trial but this program belongs to the parent company rather than directly to Philochem.[1][5]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesAntibody-drug conjugatesRadiolabeled ligandsMonoclonal antibodiesPeptides
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Philochem AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Philochem AG.